114,277 Shares in Haemonetics Corporation $HAE Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Haemonetics Corporation (NYSE:HAE) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 114,277 shares of the medical instruments supplier’s stock, valued at approximately $6,441,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.25% of Haemonetics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of HAE. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 48.6% in the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Haemonetics by 994.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after purchasing an additional 233,119 shares in the last quarter. North Peak Capital Management LLC raised its holdings in Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its holdings in Haemonetics by 17.3% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after buying an additional 124,020 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 3.7%

Shares of HAE stock opened at $85.63 on Thursday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a market cap of $3.89 billion, a P/E ratio of 42.39, a PEG ratio of 1.66 and a beta of 0.52. The company has a 50 day moving average of $74.25 and a 200-day moving average of $66.05. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the business earned $1.24 earnings per share. Haemonetics’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts anticipate that Haemonetics Corporation will post 5.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a report on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a report on Friday, June 26th. Citigroup reaffirmed a “buy” rating on shares of Haemonetics in a research report on Wednesday. JPMorgan Chase & Co. cut their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.